Amgen Greater China Ltd. has opened offices in Beijing andGuangzhou, and will open another in Shanghai by the end ofFebruary.

Based in Thousand Oaks, Calif., Amgen Inc. said the office willprovide promotional and technical support for sales of its drugEpogen, approved in China in 1992 for treatment of chronicrenal failure in patients undergoing kidney dialysis, andFilgrastim (sold in the U.S. as Neupogen and in China as Gran)for treatment of cancer patients undergoing chemotherapy.Both products are co-promoted in the People's Republic ofChina by Amgen Greater China Ltd. and Kirin Pharmaceuticals.

Amgen Greater China Ltd. was formally established with aHong Kong office in August 1992.

(c) 1997 American Health Consultants. All rights reserved.